FDA Grants Orphan Drug Designation to Roxadustat for Myelodysplastic Syndromes Treatment
Key Insights
FibroGen announced that the FDA's Office of Orphan Products Development has granted roxadustat Orphan Drug Designation for treating myelodysplastic syndromes (search) (MDS).
Post-hoc analysis from the Phase 3 MATTERHORN trial showed roxadustat improved transfusion-independence in patients with high transfusion burden compared to placebo.
The company plans to finalize and submit a Phase 3 protocol for this patient population to the FDA in the fourth quarter of 2025.
FibroGen, Inc. announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted roxadustat Orphan Drug Designation for the treatment of myelodysplastic syndromes (search) (MDS). The designation recognizes the significant unmet medical need in this rare disease affecting fewer than 200,000 people in the United States.
Clinical Evidence Supporting the Designation
The FDA's decision was supported by promising data from a post-hoc analysis of the Phase 3 MATTERHORN trial, where roxadustat demonstrated improvement in transfusion-independence compared to placebo in a subset of patients with high transfusion burden. This finding is particularly significant given the limited treatment options available for MDS patients who fail to respond to first-line therapies.
"The Orphan Drug Designation granted to roxadustat for MDS underscores the significant treatment gap in this indication, and highlights patients' need for additional convenient treatments that can provide durable response," said Thane Wettig, Chief Executive Officer of FibroGen. "Roxadustat showed an improvement in transfusion-independence in a subset of patients with high transfusion burden in a post-hoc analysis from the Phase 3 MATTHERHORN trial, which along with its favorable tolerability profile and oral route of administration has the ability to set it apart from current second-line treatments."
Addressing Critical Unmet Medical Need
Myelodysplastic syndromes (search) represent a group of disorders characterized by dysfunctional progenitor blood cells and stem cells, resulting in chronic anemia (search) in most patients. The disease burden is substantial, with approximately 58,000 patients diagnosed with lower-risk MDS in the U.S., and 85% of them suffering from anemia.
The clinical impact of MDS-associated anemia (search) is severe. Approximately 80% of patients with MDS have anemia at diagnosis, and around 60% will experience severe anemia (hemoglobin <8 g/dL) during their disease course. About 50% of patients require regular red blood cell transfusions, leading to higher rates of cardiac events, infections, and iron overload complications.
Current treatment limitations are significant. First-line treatments lead to transfusion independence in less than 50% of patients, with relief often being temporary and limited options available for second-line and beyond treatments. Existing therapies include erythropoiesis-stimulating agents (ESAs), luspatercept, imetelstat, lenalidomide for lower-risk MDS with isolated del(5q), and hypomethylating agents for higher-risk disease. Only 35-40% of patients respond to current treatments, and response durability is short.
Roxadustat's Unique Mechanism and Advantages
Roxadustat represents the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. The oral medication offers a significant advantage over current treatments, which are challenging to dose-calibrate and can only be administered via subcutaneous injection or IV infusion.
The drug is already approved in Europe, Japan, and numerous other countries for treating anemia (search) of chronic kidney disease (search) in adult patients on dialysis and not on dialysis, demonstrating its established safety and efficacy profile in anemia management.
Development Timeline and Regulatory Benefits
FibroGen is finalizing the Phase 3 protocol for the MDS patient population and plans to submit it to the FDA in the fourth quarter of 2025. The Orphan Drug Designation provides several regulatory advantages, including exemption from certain FDA fees, financial incentives for qualified clinical development, and seven years of market exclusivity in the U.S. following drug approval.
The designation highlights the FDA's recognition of the urgent need for new treatment options in MDS, where patients face significant quality of life impacts from anemia (search)-related fatigue, cognitive dysfunction, and cardiovascular complications associated with transfusion dependence.